###begin article-title 0
Imprinted CDKN1C Is a Tumor Suppressor in Rhabdoid Tumor and Activated by Restoration of SMARCB1 and Histone Deacetylase Inhibitors
###end article-title 0
###begin p 1
Conceived and designed the experiments: EMA DA. Performed the experiments: EMA AM VD CR. Analyzed the data: EMA AM VD DA. Contributed reagents/materials/analysis tools: EMA CWC JB PE RS JMC RJ. Wrote the paper: EMA DA.
###end p 1
###begin p 2
###xml 0 7 0 7 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMARCB1</italic>
###xml 300 307 300 307 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMARCB1</italic>
###xml 518 524 518 524 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN1C</italic>
###xml 960 966 960 966 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN1C</italic>
###xml 1090 1096 1090 1096 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKNIC</italic>
###xml 1195 1201 1195 1201 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN1C</italic>
SMARCB1 is deleted in rhabdoid tumor, an aggressive paediatric malignancy affecting the kidney and CNS. We hypothesized that the oncogenic pathway in rhabdoid tumors involved epigenetic silencing of key cell cycle regulators as a consequence of altered chromatin-remodelling, attributable to loss of SMARCB1, and that this hypothesis if proven could provide a biological rationale for testing epigenetic therapies in this disease. We used an inducible expression system to show that the imprinted cell cycle inhibitor CDKN1C is a downstream target for SMARCB1 and is transcriptionally activated by increased histone H3 and H4 acetylation at the promoter. We also show that CDKN1C expression induces cell cycle arrest, CDKN1C knockdown with siRNA is associated with increased proliferation, and is able to compete against the anti-proliferative effect of restored SMARCB1 expression. The histone deacetylase inhibitor (HDACi), Romidepsin, specifically restored CDKN1C expression in rhabdoid tumor cells through promoter histone H3 and H4 acetylation, recapitulating the effect of SMARCB1 on CDKNIC allelic expression, and induced cell cycle arrest in G401 and STM91-01 rhabdoid tumor cell lines. CDKN1C expression was also shown to be generally absent in clinical specimens of rhabdoid tumor, however CDKN1A and CDKN1B expression persisted. Our observations suggest that maintenance of CDKN1C expression plays a critical role in preventing rhabdoid tumor growth. Significantly, we report for the first time, parallels between the molecular pathways of SMARCB1 restoration and Romidepsin treatment, and demonstrate a biological basis for the further exploration of histone deacetylase inhibitors as relevant therapeutic reagents in the treatment of rhabdoid tumor.
###end p 2
###begin title 3
Introduction
###end title 3
###begin p 4
###xml 594 601 594 601 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMARCB1</italic>
###xml 616 619 616 619 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004482-Versteege1">[1]</xref>
###xml 621 624 621 624 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004482-Biegel1">[2]</xref>
###xml 626 629 626 629 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004482-Savla1">[3]</xref>
###xml 631 634 631 634 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004482-Sevenet1">[4]</xref>
###xml 636 639 636 639 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004482-Taylor1">[5]</xref>
###xml 641 644 641 644 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004482-RousseauMerck1">[6]</xref>
###xml 173 181 <span type="species:ncbi:9606">children</span>
Rhabdoid tumor (RT) is an aggressive although rare tumor of infancy and early childhood resistant to conventional chemotherapies and radiotherapy. The majority of afflicted children succumb to their disease within several months of diagnosis. Rhabdoid tumors mainly arise in the kidney where they are known as rhabdoid tumours and in the central nervous system where they are referred to as Atypical Teratoid Rhabdoid Tumor (AT/RT). They are characterized genetically by deletion or allelic loss of chromosome 22q, and associated inactivating mutations or deletion of the tumor suppressor gene SMARCB1 (OMIM 601607) [1], [2], [3], [4], [5], [6].
###end p 4
###begin p 5
###xml 23 30 23 30 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">smarcb1</italic>
###xml 162 165 162 165 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004482-Guidi1">[7]</xref>
###xml 167 170 167 170 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004482-KlochendlerYeivin1">[8]</xref>
###xml 172 175 172 175 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004482-Roberts1">[9]</xref>
###xml 230 233 230 233 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p53</italic>
###xml 242 246 242 246 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004482-Roberts2">[10]</xref>
###xml 411 415 411 415 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004482-KlochendlerYeivin2">[11]</xref>
###xml 426 433 426 433 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMARCB1</italic>
###xml 489 496 489 496 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMARCB1</italic>
###xml 593 597 593 597 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004482-Modena1">[12]</xref>
###xml 599 603 599 603 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004482-Hulsebos1">[13]</xref>
###xml 34 38 <span type="species:ncbi:10090">mice</span>
###xml 82 86 <span type="species:ncbi:10090">mice</span>
###xml 143 148 <span type="species:ncbi:9606">human</span>
###xml 196 200 <span type="species:ncbi:10090">mice</span>
Homozygous deletion of smarcb1 in mice is embryonic lethal, however, heterozygous mice develop tumors that are histologically similar to their human counterparts [7], [8], [9]. Tumor formation in mice is accelerated by coincident p53 mutation[10] and it has been recently proposed that tumor formation associated with loss of SMARCB1 may arise due to permissive defects in cellular DNA damage response pathways [11]. Although SMARCB1 deletion is predominantly associated with RT, recently SMARCB1 inactivation and mutation has been described in epitheloid sarcoma and familial schwannomatosis [12], [13].
###end p 5
###begin p 6
###xml 41 48 41 48 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMARCB1</italic>
###xml 134 141 134 141 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMARCB1</italic>
###xml 225 232 225 232 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMARCB1</italic>
###xml 284 288 284 288 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004482-Chai1">[14]</xref>
###xml 290 294 290 294 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004482-Oruetxebarria1">[15]</xref>
###xml 334 342 334 342 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p16INK4a</italic>
###xml 347 353 347 353 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN1A</italic>
###xml 404 412 404 412 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">cyclin A</italic>
###xml 414 418 414 418 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E2F1</italic>
###xml 423 427 423 427 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDC6</italic>
###xml 498 501 498 501 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">pRB</italic>
###xml 501 505 501 505 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004482-Versteege2">[16]</xref>
###xml 562 565 562 565 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">pRB</italic>
###xml 145 150 <span type="species:ncbi:9606">human</span>
One suggested mechanism by which loss of SMARCB1 facilitates oncogenesis is through defective cell cycle regulation. Re-expression of SMARCB1 in human rhabdoid tumor cell lines causes G0/G1 arrest showing that restoration of SMARCB1 expression is sufficient to suppress proliferation [14], [15]. This is associated with activation of p16INK4a and CDKN1A and down regulation of E2F target genes including cyclin A, E2F1 and CDC6. SMARCB1 arrest is critically dependent on the presence of functional pRB[16]. SMARCB1 is not able to arrest cells lacking functional pRB and arrest can also be reversed by disruption of pRB repressor complexes through restoration of cyclin D1 and cyclin E expression. Further, constituitively active pRB1 can induce arrest in RT cell lines lacking SMARCB1.
###end p 6
###begin p 7
###xml 87 91 87 91 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004482-Doan1">[17]</xref>
###xml 313 317 306 310 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004482-Versteege2">[16]</xref>
###xml 519 523 512 516 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Brg1</italic>
###xml 528 531 521 524 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Brm</italic>
###xml 637 641 630 634 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CD44</italic>
###xml 646 656 639 649 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E-Cadherin</italic>
###xml 705 709 698 702 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004482-Banine1">[18]</xref>
###xml 989 993 982 986 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004482-Pan1">[19]</xref>
###xml 1032 1037 1025 1030 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">c-Fos</italic>
###xml 1175 1179 1168 1172 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004482-Zhang1">[20]</xref>
SMARCB1 is part of an ATP dependent multiprotein SWI/SNF chromatin remodelling complex [17]. It associates with ATPase subunits Brg1 (for Brahma-related gene 1, or SNF2beta and Brm (for Brahma or SNF2alpha). In contrast to SMARCB1, Brg1 and Brm are required for cell cycle arrest mediated by pRB. Versteege et al [16] hypothesize that Brg1 and Brm are necessary for the chromatin remodelling associated with pRB repression of E2F and that SMARCB1 has a promoting but not a primary role in this remodelling. Deletion of Brg1 and Brm occurs in many cancer cell lines and is associated with gene specific changes in promoter methylation at CD44 and E-Cadherin leading to hyper-methylation and gene silencing [18]. Brg1 and Brm associate directly with the promoters of these genes and a more widespread role in epigenetic regulation of gene expression during tumor progression has been proposed. The direct role of SMARCB1 in chromatin remodelling has not been extensively explored. Pan et al [19] have shown that SMARCB1 represses the c-Fos promoter via histone deacetylation in 293T cells and that this occurs via direct interactions between HDAC4 and SMARCB1, and Zhang et al [20] showed that interactions between HDAC1 and hSNF5/INI1 (SMARCB1) were required to repress Cyclin D.
###end p 7
###begin p 8
###xml 54 61 54 61 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMARCB1</italic>
###xml 375 381 375 381 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN1C</italic>
###xml 423 430 423 430 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMARCB1</italic>
###xml 544 550 544 550 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN1C</italic>
###xml 1052 1058 1052 1058 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN1C</italic>
We hypothesized that the oncogenic pathway induced by SMARCB1 inactivation in RT may involve epigenetic silencing of key cell cycle target genes. This premise, if established, may reveal opportunities for treatment of RT with epigenetic therapies that restore the expression of key growth-regulating genes. In this work we demonstrate that the imprinted cell cycle inhibitor CDKN1C (OMIM 600856) is a downstream target for SMARCB1 epigenetic regulation. SMARCB1 consistently activated CDKN1C expression via histone H3 and H4 acetylation at the CDKN1C promoter and the histone deacetylase inhibitor (HDACi), romidepsin, restored imprinted CDKN1C expression in RT cells through promoter histone H3 and H4 acetylation. Significantly, CDKN1C expression was absent or negligible in clinical specimens, enforced expression of CDKN1C in G401 RT cells induced cell cycle arrest and knockdown of endogenous CDKN1C increased proliferation in G401 RT cells as well as attenuating the effects of SMARCB1 re-expression on cell proliferation. Our findings show that CDKN1C silencing is common in RT, suggest that CDKN1C is an important regulator of RT cell growth, and that RT cell proliferation is mediated in part via suppression of CDKN1C expression attributable to deletion of SMARCB1.
###end p 8
###begin title 9
Results
###end title 9
###begin title 10
CDKN1C is up-regulated in RT cells with reconstituted expression of SMARCB1
###end title 10
###begin p 11
###xml 11 15 11 15 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Kip2</sup>
###xml 186 190 186 190 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Kip2</sup>
###xml 271 278 271 278 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMARCB1</italic>
###xml 436 443 436 443 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMARCB1</italic>
###xml 443 446 443 446 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004482-Versteege1">[1]</xref>
###xml 539 546 539 546 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMARCB1</italic>
###xml 710 717 710 717 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMARCB1</italic>
CDKN1C (p57Kip2) is commonly epigenetically silenced in cancer and is the only imprinted member of the CIP KIP family of cell cycle inhibitors. We hypothesized therefore that CDKN1C (p57Kip2) may be a potential downstream target for SMARCB1. To examine this we expressed SMARCB1 under the control of an inducible promoter in two renal RT cell lines, G401 and STM91-01. G401 is an established renal RT cell line homozygously deleted for SMARCB1[1]. STM91-01 is derived from a lung metastasis with 22q loss of heterozygosity and deletion of SMARCB1 exons 1 to 5 on the retained allele. Deletion of SMARCB1 protein in all RT cell lines used in the study was confirmed by Western blotting and further evidence for SMARCB1 deletion or rearrangement was obtained by southern blotting (results not shown).
###end p 11
###begin p 12
###xml 507 516 507 516 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004482-g001">Figure 1A</xref>
###xml 699 700 699 700 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">0</sub>
###xml 761 771 761 771 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0004482.s001">Figure S1A</xref>
###xml 861 865 861 865 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004482-Chai1">[14]</xref>
###xml 866 870 866 870 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004482-Versteege2">[16]</xref>
###xml 978 988 978 988 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0004482.s001">Figure S1A</xref>
###xml 1216 1220 1216 1220 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004482-Reincke1">[21]</xref>
###xml 1637 1646 1637 1646 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004482-g001">Figure 1B</xref>
###xml 1866 1875 1866 1875 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004482-g001">Figure 1C</xref>
###xml 2322 2331 2322 2331 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004482-g001">Figure 1D</xref>
G401 clones expressing SMARCB1 under the control of a tamoxifen inducible promoter system (pcDNA3 UAS SMARCB1 and pEF puro/GEV) were selected in geneticin and puromycin. Two G401 clones, F13 and F22, showing inducible SMARCB1 expression, were selected for further investigation. A pool of STM91-01 cells (STMpc), transduced with a lentiviral vector system (pF 5xUAS Sv40 puro/ini1 and pF GEV16) was also examined. SMARCB1 protein was readily detectable 24 hours after exposure to 1 uM 4HT in all cultures, (Figure 1A). Cell cycle analysis was performed on cultures of F22 cells 72 hours after induction of SMARCB1 protein expression. In SMARCB1 expressing cells 41.4+/-5% of cells were arrested in G0 compared with 7.0+/-1.4% in un-induced cells (Supplementary Figure S1A), consistent with observations made previously that SMARCB1 can induce cell cycle arrest [14]-[16]. In contrast, STMpc cells induced to express SMARCB1 showed little change in the cell cycle (Supplementary Figure S1A). One explanation for this is that the parental line, STM91-01, is derived from a RT lung metastasis and may have acquired additional oncogenic mutations and hence greater resistance to growth inhibitory signals. Reincke et al [21] also found this cell line difficult to transduce with recombinant adenovirus containing SMARCB1 and reportedly found inconsistent cell cycle changes following infection. CDKN1C mRNA was elevated in all lines (F22, F13, STMpc) following induction of SMARCB1 expression with 1 uM 4HT whereas other CDK family members including CDKN1A (p21/WAF1) and CDKN1B (p27) did not show uniform responses following 4HT treatment (Figure 1B). Quantitative analysis of CDKN1C expression by real-time PCR in F22 cells showed four-fold increases in CDKN1C expression 24 hours following SMARCB1 induction, and STMpc showed six-fold increases in CDKN1C expression (Figure 1C). 1 uM 4HT alone had a negligible effect on CDKN1C expression in parental G401 and STM91-01 cultures demonstrating that the observed effect on CDKN1C expression was directly attributable to the induction of SMARCB1 protein (results not shown). Endogenous levels of CDKN1C protein were low in un-induced F22 cells however following SMARCB1 induction, were increased to levels consistent with the proportional increase in CDKN1C transcript levels (Figure 1D).
###end p 12
###begin title 13
SMARCB1 induces CDKN1C expression in rhabdoid tumor cell lines.
###end title 13
###begin p 14
(A). Western blot showing induction of SMARCB1 protein in G401 clones F13 and F22, and in a transduced pool of STM91-01 cells, STMpc. Lanes show protein in un-induced (-) cells and in cells induced with 4HT (+). (B) Gene expression examined by RT-PCR for CDKN1C, CDKN1B, CDKN1A and the HPRT control gene in un-induced (-) and in 4HT-induced (+) cells. The -ve lane represents the PCR negative control, the RNA -ve control lane represents the negative control for reverse transcription and the RT-ve control represents a control for genomic contamination derived from the induced F22 sample. CDKN1C was amplified for 40 cycles and CDKN1B and CDKN1A for 28 cycles. All primers were located in separate exons. (C) CDKN1C expression normalized to the GUSB control gene, derived by real-time quantitative pcr in un-induced (-4HT) and in induced (+4HT) cultures of F22 cells (upper panel) and in cultures of STMpc cells (lower panel). The data represent the mean of three independent experiments and the error bars represent the standard error of the mean. (D) Western blot showing expression of endogenous CDKN1C protein pre and post SMARCB1 induction with 4HT. Immunoblotting was performed with the p57 Kip2 antibody from Cell Signaling Technologies with an exposure time of 2 minutes.
###end p 14
###begin title 15
Enforced expression of CDKN1C arrests proliferation in G401 cells and CDKN1C knock-down increases proliferation and attenuates SMARCB1-induced proliferation arrest
###end title 15
###begin p 16
###xml 338 347 338 347 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004482-g002">Figure 2A</xref>
###xml 366 376 366 376 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0004482.s001">Figure S1B</xref>
###xml 627 628 627 628 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">0</sub>
###xml 694 704 694 704 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0004482.s001">Figure S1B</xref>
###xml 1234 1243 1234 1243 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004482-g002">Figure 2B</xref>
###xml 123 128 <span type="species:ncbi:9606">human</span>
To examine the direct effect of induced CDKN1C expression in rhabdoid tumor cells, G401 clones over-expressing full-length human CDKN1C under the control of the tamoxifen inducible promoter (pcDNA3 UAS CDKN1C and pEFpuro/GEV), were selected in geneticin and puromycin. Induction of CDKN1C protein in G401 cells induced cell cycle arrest (Figure 2A and Supplementary Figure S1B). Endogenous CDKN1C protein was not detectable by Western blotting at the short exposure time-setting used to detect over-expression of CDKN1C. In clone G401 C1, expressing the highest level of CDKN1C protein, 24.7+/-1.67% of cells were arrested in G0, compared with 2.3+/-0.14% in un-induced cultures (Supplementary Figure S1B). To further ascertain the functional significance of CDKN1C induction in RT cells, a CDKN1C siRNA pool was used to knock-down the low level of endogenous CDKN1C in F22 cells, and to knock-down CDKN1C mRNA induced following SMARCB1 re-expression. CDKN1C siRNA transfection in F22 cells eliminated CDKN1C expression and led to increased proliferation, as measured by a greater positive change in MTS absorbance over the first 48 hours following transfection, as compared with F22 cells treated with a non-targeting control siRNA (Figure 2B). CDKN1C siRNA also attenuated the effect of SMARCB1 induction on restricting cell proliferation. Cells in which SMARCB1 expression was induced with 1 uM 4HT by 24 hours and transfected with CDKN1C siRNA, exhibited a significant and reproducible positive increase in MTS absorbance between 24 and 48 hours, reflecting an increase in the number of proliferating cells in the culture when compared with cells transfected with non-targeting siRNA +4HT. This correlated with reduced levels of CDKN1C mRNA after 48 hours in the +4HT CDKN1C siRNA-treated cultures. Between 48 and 72 hours, cells in the 4HT and non-targeting siRNA, CDKN1C siRNA, and CDKN1C siRNA and 4HT cultures, showed a reduction in the number of viable cells present. In the CDKN1C siRNA culture this likely reflects a reduction in the rate of cell proliferation as the cells approach senescence. In the cultures treated with non-targeting siRNA and 4HT, and CDKN1CsiRNA and 4HT, the decrease in cell viability probably reflects the long-term effect of sustained SMARCB1 expression on cell viability. This may suggest that SMARCB1 modifies the expression of other genes in addition to CDKN1C that affect cell proliferation and viability. Nevertheless these results clearly show that CDKN1C is an important modulator of G401 growth as small changes in CDKN1C expression affect proliferation, and furthermore provide evidence for parallels between the actions of SMARCB1 and CDKN1C in regulating RT proliferation.
###end p 16
###begin title 17
CDKN1C levels modulate growth in rhabdoid tumor cells.
###end title 17
###begin p 18
(A) Western blot showing induction of CDKN1C protein in G401 clones C1 and C2. Western blotting was performed with the p57 (C20) antibody (Santa Cruz Biotech) with an exposure time of 30 seconds. (B) MTS proliferation assay and CDKN1C RT-PCR following siRNA treatment in F22 cells. The bar graph represents the absorbance difference at each time interval. The data shown is the mean of five independent experiments and the error bars represent the standard error of the mean. CDKN1C siRNA leads to increased proliferation in F22 cells and attenuated proliferation arrest in the 24 to 48 hour time interval in F22 cells induced to express SMARCB1. These effects were positively correlated with the levels of CDKN1C expression following CDKN1C siRNA transfection determined after 35 PCR cycles (lower panel).
###end p 18
###begin title 19
###xml 63 69 63 69 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN1C</italic>
SMARCB1 expression causes increased histone acetylation at the CDKN1C promoter
###end title 19
###begin p 20
###xml 147 153 147 153 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN1C</italic>
###xml 390 394 390 394 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004482-Kikuchi1">[22]</xref>
###xml 481 487 481 487 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN1C</italic>
###xml 626 635 626 635 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0004482.s002">Figure S2</xref>
To investigate the mechanism associated with the SMARCB1-induced upregulation of CDKN1C in RT cells, a region within the 5'CpG island spanning the CDKN1C transcription start site, from -41 to +114 was analysed for changes in methylation, pre and post SMARCB1 induction. Methylation of this region has previously been shown to correlate with silencing CDKN1C expression in cancer cell lines [22]. Bisulphite sequencing on 10 clones pre and post induction with 4HT revealed that the CDKN1C promoter was largely unmethylated in un-induced F22 and STMpc cells and remained unmethylated following SMARCB1 induction, (Supplementary Figure S2). Furthermore, treatment of parental G401 and STM91-01 cells with 2 uM 5aza2dC had no significant effect on CDKN1C expression consistent with a lack of promoter methylation.
###end p 20
###begin p 21
###xml 18 24 18 24 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN1C</italic>
###xml 215 221 215 221 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN1C</italic>
###xml 287 291 287 291 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004482-Kikuchi1">[22]</xref>
###xml 396 402 396 402 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN1C</italic>
###xml 654 669 654 669 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004482-g003">Figure 3A and B</xref>
###xml 717 723 717 723 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN1A</italic>
###xml 728 734 728 734 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN1B</italic>
###xml 793 799 793 799 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN1C</italic>
###xml 855 861 855 861 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN1A</italic>
###xml 895 901 895 901 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN1B</italic>
###xml 1018 1033 1018 1033 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004482-g003">Figure 3C and D</xref>
###xml 1118 1124 1118 1124 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN1C</italic>
We then performed CDKN1C promoter chromatin immunoprecipitation (ChIP) with antibodies to acetylated histones H3 and H4, 48 hours post SMARCB1 induction. Quantitative PCR was performed on recovered DNA spanning the CDKN1C transcription start site from -72 to +89 and normalized to GAPDH [22]. Three independent ChIP analyses each, on both F22 and STMpc rhabdoid tumor cell lines, showed that the CDKN1C promoter is acetylated in un-induced F22 and STMpc cells, however histone H3 acetylation increased 2 fold in both cell lines following SMARCB1 induction with 4HT. A less marked increase in histone H4 acetylation was observed in both cell lines cells (Figure 3A and B). Histone acetylation was also examined at the CDKN1A and CDKN1B promoters in F22 cells. In contrast to acetylation of the CDKN1C promoter, histone H3 acetylation was either unchanged (CDKN1A promoter) or slightly decreased (CDKN1B promoter) following SMARCB1 induction, and histone H4 acetylation was not significantly changed at either promoter (Figure 3C and D). These results show that SMARCB1 specifically acetylates histones H3 and H4 at the CDKN1C promoter either directly, or indirectly through the recruitment of histone acetyltransferases (HATs) or through inhibition of histone deacetylases (HDACs).
###end p 21
###begin title 22
SMARCB1 increases histone acetylation at the CDKN1C promoter.
###end title 22
###begin p 23
###xml 52 58 52 58 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN1C</italic>
###xml 174 180 174 180 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN1C</italic>
###xml 339 345 339 345 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN1C</italic>
###xml 436 442 436 442 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN1A</italic>
###xml 505 511 505 511 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN1B</italic>
(A) Acetylation of histone H3 and histone H4 at the CDKN1C promoter in un-induced (-4HT) and in induced (+4HT) F22 cells. (B) Acetylation of histone H3 and histone H4 at the CDKN1C promoter in un-induced (-4HT) and in induced (+4HT) STMpc cells. CDKN1C signal was normalized to GAPDH. Acetylation at histone H3 and H4 was increased at the CDKN1C promoter in both F22 and STMpc cells. (C) Acetylation of histone H3 and histone H4 at the CDKN1A promoter. (D) Acetylation of histone H3 and histone H4 at the CDKN1B promoter. CDKN1A and CDKN1B signal was normalized to GAPDH. Error bars represent the standard error of the mean and were derived from three independent experiments.
###end p 23
###begin title 24
###xml 0 6 0 6 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN1C</italic>
CDKN1C is upregulated in RT cells by HDACi and promoter histone acetylation is increased
###end title 24
###begin p 25
###xml 105 109 105 109 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004482-Bhalla1">[23]</xref>
###xml 172 178 172 178 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN1C</italic>
###xml 349 363 349 363 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004482-g004">Figure 4A to D</xref>
###xml 1119 1120 1119 1120 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">0</sub>
###xml 1136 1144 1136 1144 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0004482.s006">Table S1</xref>
###xml 1293 1294 1293 1294 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">0</sub>
###xml 1429 1430 1429 1430 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">0</sub>
###xml 1487 1493 1487 1493 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN1C</italic>
###xml 1673 1679 1673 1679 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN1C</italic>
###xml 1759 1768 1759 1768 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004482-g005">Figure 5A</xref>
###xml 1836 1842 1836 1842 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN1A</italic>
###xml 1921 1927 1921 1927 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN1C</italic>
###xml 1929 1938 1929 1938 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004482-g005">Figure 5B</xref>
###xml 2060 2069 2060 2069 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004482-g005">Figure 5C</xref>
Romidepsin is a potent broad-spectrum inhibitor of class 1 and class II histone decetylases (reviewed in [23]). We reasoned that HDACi might mimic the effect of SMARCB1 on CDKN1C. CDKN1C expression was significantly increased in all RT cell lines including G401, STM91-01, SJSC and BT16 lines following treatment with 10 nM Romidepsin for 24 hours (Figure 4A to D). Levels of CDKN1C mRNA induction quantified by real-time PCR varied from six-fold in BT16 cells to twelve-fold in STM91-01 cells. After 48 hours culture with 10 nM Romidepsin, cells showed signs of apoptosis. This coincided with a decrease in the levels of the GUSB house-keeping gene therefore the levels of CDKN1C induction at 24 hours most reliably reflect the true effect of Romidepsin on CDKN1C expression. The levels of CDKN1C induction at 24 hours in G401 and STM91-01 cells treated with Romidepsin slightly exceeded those induced with SMARCB1. Cell cycle analysis was performed on G401 and STM91-01 cells treated with 1 nM Romidepsin after 72 hours. In both cell lines, this treatment led to a significant increase in the percentage of cells in G0 (Supplementary Table S1). This was more pronounced in G401 cells compared with STM91-01 cells. In control G401 cells treated with 0.01% DMSO, 4.1+/-0.35% of cells were in G0 compared with 19.3+/-1.6% in cultures treated with 1 nM Romidepsin. In STM91-01, 9.3+/-1.9% of cells treated with 0.01% DMSO were in G0 compared with 16.7+/-2.0% treated with 1 nM Romidepsin. CDKN1C promoter ChIP analysis was performed in G401 and STM91-01 post treatment with 10 nM Romidepsin for 48 hours. Both histone H3 and H4 acetylation was significantly increased at the CDKN1C promoter in treated cells, consistent with the increase in CDKN1C expression, (Figure 5A). Increases in promoter histone acetylation were also observed for CDKN1A however, these were not as pronounced as the histone acetylation observed for CDKN1C (Figure 5B). In contrast, CDKN1B did not show significant increases in promoter histone acetylation following Romidepsin treatment (Figure 5C).
###end p 25
###begin title 26
Romidepsin increases CDKN1C expression in rhabdoid tumor.
###end title 26
###begin p 27
CDKN1C expression normalized to the GUSB control gene in (A) G401 (B) STM91-01 (C) SJSC and in (D) BT16 cells treated with 10 nM Romidepsin. All data represent the mean of three independent experiments and the error bars represent the standard error of the mean.
###end p 27
###begin title 28
Romidepsin increases histone acetylation at the CDKN1C promoter.
###end title 28
###begin p 29
###xml 52 58 52 58 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN1C</italic>
###xml 325 331 325 331 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN1A</italic>
###xml 692 698 692 698 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN1B</italic>
(A) Acetylation of histone H3 and histone H4 at the CDKN1C promoter in G401 and in STM91-01 cells treated with 10 nM Romidepsin and in control cells treated with 0.01%DMSO. Acetylation at both histone H3 and histone H4 was significantly increased in both treated cultures. (B) Acetylation of histone H3 and histone H4 at the CDKN1A promoter in G401 and in STM91-01 cells treated with 10 nM Romidepsin and in control cells treated with 0.01%DMSO. Histone acetylation is increased in both cell lines following Romidepsin treatment although the increases are not as marked as those seen at the CDKN1C promoter following Romidepsin treatment. (C). Acetylation of histone H3 and histone H4 at the CDKN1B promoter in G401 and in STM91-01 cells treated with 10 nM Romidepsin and in control cells treated with 0.01%DMSO.
###end p 29
###begin title 30
###xml 0 6 0 6 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN1C</italic>
CDKN1C allelic expression is modulated in RT cells with reconstituted expression of SMARCB1 and with HDACi
###end title 30
###begin p 31
###xml 11 17 11 17 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN1C</italic>
###xml 81 87 81 87 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN1C</italic>
###xml 126 130 126 130 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004482-Matsuoka1">[24]</xref>
###xml 132 136 132 136 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004482-Algar1">[25]</xref>
###xml 138 144 138 144 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN1C</italic>
###xml 261 270 261 270 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0004482.s003">Figure S3</xref>
###xml 375 381 375 381 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN1C</italic>
###xml 458 462 458 462 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004482-Algar2">[26]</xref>
###xml 500 506 500 506 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN1C</italic>
###xml 821 827 821 827 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN1C</italic>
###xml 873 882 873 882 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004482-g006">Figure 6A</xref>
###xml 1200 1206 1200 1206 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN1C</italic>
###xml 1434 1440 1434 1440 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN1C</italic>
###xml 1592 1601 1592 1601 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004482-g006">Figure 6A</xref>
###xml 1830 1839 1830 1839 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004482-g006">Figure 6B</xref>
###xml 2024 2033 2024 2033 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004482-g006">Figure 6B</xref>
###xml 2176 2185 2176 2185 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004482-g006">Figure 6B</xref>
###xml 2321 2327 2321 2327 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN1C</italic>
To examine CDKN1C imprinting, we took advantage of deletion polymorphisms within CDKN1C exon 1 in G401 and in STM91-01 cells, [24], [25]. CDKN1C alleles differing in size by 24 bp and 12 bp were identified in G401 and STM91-01 cells respectively (Supplementary Figure S3). Both cell lines exhibited biallelic expression, suggesting loss of imprinting. This is in contrast to CDKN1C imprinting in the normal kidney where the gene shows monoallelic expression [26]. The effect of SMARCB1 expression on CDKN1C imprinting in G401 clones F13 and F22 and in the STM91-01 pooled cells, STMpc, was examined. Induction of SMARCB1 protein in F22 cells led to the restoration of monoallelic CDKN1C expression with expression predominantly from the short allele 24 hours post induction, and a trend towards expression from the short CDKN1C allele in the weaker SMARCB1 expressor, F13 (Figure 6A). 4HT alone had no sustained effect on the pattern of allelic expression in parental G401 cells, demonstrating specificity for the SMARCB1 effect. A variable dominant expression from the long allele was sometimes observed in different wild-type and recombinant un-induced G401 cells reflecting the unstable nature of CDKN1C imprinting in these cultures. The short allele was however always reproducibly expressed in replicate cultures following SMARCB1 induction in the G401 background suggesting that SMARCB1 expression leads to stabilization of the CDKN1C imprint and promotes monoallelic expression. In contrast, induction of SMARCB1 expression in STMpc cells did not alter biallelic expression of CDKN1C (Figure 6A). We then examined allelic expression in response to treatment with 0.3 uM TSA and 10 nM Romidepsin and observed a shift to the short allele mimicking the effect of SMARCB1 induction. This was most marked with 10 nM Romidepsin (Figure 6B). The parental G401 line was also sensitive to TSA and Romidepsin, and the direction of monoallelic expression following treatment was identical to that observed in F22 and F13 cells (Figure 6B). Consistent with the response to SMARCB1 induction, TSA and Romidepsin had no effect on the pattern of allelic expression in STM91-01 cells (Figure 6B). Taken together these results show that SMARCB1 over-expression, and HDACi drugs, have identical affects on the allelic expression of CDKN1C.
###end p 31
###begin title 32
SMARCB1 and HDACi have identical effects on allelic expression of CDKN1C.
###end title 32
###begin p 33
###xml 4 10 4 10 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN1C</italic>
###xml 356 362 356 362 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN1C</italic>
###xml 426 432 426 432 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN1C</italic>
(A) CDKN1C allelic expression in un-induced and in induced cultures of G401, F22, F13, STM91-01 and in STMpc cells. Changes in the pattern of allelic expression can be seen in F22 and in F13 cells following induction of SMARCB1 expression with 1 uM 4HT. Wild-type G401 cells did not show any change in allelic expression following 4HT treatment. Biallelic CDKN1C expression persisted in STM91-01 cells and in STMpc cells. (B) CDKN1C allelic expression in un-induced cultures of F22 and F13 with 0.01% DMSO and 10 nM Romidepsin and in G401 cells. Changes in allelic expression can be seen with Romidepsin treatment in F13, F22 cells and in wild-type G401 cells. As with SMARCB1 induction in STMpc cells, allelic expression in STM91-01 cells was unchanged following Romidpesin treatment.
###end p 33
###begin p 34
###xml 14 20 14 20 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN1C</italic>
###xml 175 178 175 178 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IC2</italic>
###xml 242 246 242 246 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004482-Smilinich1">[27]</xref>
###xml 248 252 248 252 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004482-DiazMeyer1">[28]</xref>
###xml 407 410 407 410 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IC2</italic>
###xml 492 498 492 498 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN1C</italic>
###xml 543 552 543 552 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0004482.s004">Figure S4</xref>
###xml 620 626 620 626 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN1C</italic>
###xml 683 686 683 686 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IC2</italic>
Imprinting at CDKN1C is typically, although not exclusively, regulated via maintenance of allele specific patterns of methylation at the adjacent 11p15.5 Imprinting Centre 2 (IC2) involving antisense transcription of the non-coding RNA, LIT1 [27], [28]. Mosaic loss of methylation at IC2 may lead to low levels of biallelic CDKN1C expression. However, in both G401 and STM91-01 cells, normal methylation at IC2 was observed suggesting that an alternative mechanism is associated with loss of CDKN1C imprinting in RT cell lines ( Supplementary Figure S4). Other RT cell lines including SJSC and BT16 (not informative for CDKN1C imprint analysis) also maintained normal methylation at IC2 (results not shown).
###end p 34
###begin title 35
CDKN1C expression is absent in rhabdoid tumor specimens
###end title 35
###begin p 36
###xml 226 233 226 233 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMARCB1</italic>
###xml 589 599 589 599 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0004482.s005">Figure S5A</xref>
###xml 734 741 734 741 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0004482-t001">Table 1</xref>
###xml 860 867 860 867 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMARCB1</italic>
###xml 929 935 929 935 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN1C</italic>
###xml 1098 1101 1098 1101 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IC2</italic>
###xml 1183 1186 1183 1186 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IC2</italic>
###xml 1210 1216 1210 1216 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN1C</italic>
The relevance of impaired CDKN1C expression in RT cell lines to the aetiology of RT was further ascertained by examination of clinical rhabdoid tumor specimens. Tumors classified as rhabdoid or ATRT on the basis of identified SMARCB1 mutations, absence of SMARCB1 protein expression or histological criteria, were examined for CDKN1C mRNA expression by RT-PCR and for CDKN1C protein by immunohistochemistry. 6/6 tumors with viable mRNA showed negligible or absent CDKN1C expression after 45 cycles of RT-PCR, although CDKN1A and CDKN1B expression persisted in these tumors, (Supplementary Figure S5A). All tumors examined by immunohistochemistry (n = 12) lacked nuclear staining for CDKN1C and showed negligible cytoplasmic staining (Table 1 and Supplementary Figure 5B). A subset of RT show loss of CDKN1C protein even in the presence of detectable wild-type SMARCB1 suggesting that additional genetic factors may contribute to CDKN1C silencing in rhabdoid and related tumors. Four tumor specimens, with confirmed SMARCB1 mutations, and lacking CDKN1C expression, exhibited methylation indices at IC2 within the normal range (results not shown) suggesting that epigenetic change at IC2 is not responsible for CDKN1C silencing in primary rhabdoid tumors, consistent with observations in RT cell lines. There was insufficient DNA available from SMARCB1 expressing tumors for IC2 methylation analysis by southern blotting, and it is unclear whether imprinting defects at IC2 contribute to the absence of CDKN1C expression within this sub-set.
###end p 36
###begin title 37
Molecular genetic features of ATRT.
###end title 37
###begin p 38
###xml 0 7 0 7 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0004482-t001">Table 1</xref>
###xml 87 94 87 94 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMARCB1</italic>
###xml 161 168 161 168 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMARCB1</italic>
Table 1 summarizes the molecular genetics of clinical specimens of ATRT. In tumor 3074 SMARCB1 was homozygously deleted. In tumors 3161 and 3180 two independent SMARCB1 mutations were identified. NA; tumor RNA was not available.
###end p 38
###begin title 39
Discussion
###end title 39
###begin p 40
###xml 62 68 62 68 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN1C</italic>
In this study we identify the imprinted cell cycle regulator, CDKN1C, as a new and important SMARCB1 target in RT and furthermore demonstrate that SMARCB1 has the capacity to restore the expression of genes that are epigenetically silenced, consistent with its proposed role in chromatin remodelling. We show evidence that the mechanism by which CDKN1C expression is induced by SMARCB1 is via increased promoter histone H3 and H4 acetylation and that the HDACi, Romidepsin, activates CDKN1C expression in a related manner, leading to cell cycle arrest in RT cell lines. The parallel effects of SMARCB1 and HDACi, in association with an absence of CDKN1C expression in clinical specimens of rhabdoid tumor, and the demonstrated sensitivity of RT cell lines to small changes in CDKN1C expression mediated via siRNA, suggest that loss of CDKN1C is integral to the aetiology of RT, and furthermore that RT may be responsive to specific HDACi that increase endogenous levels of CDKN1C. This study reveals new insight into the molecular aetiology of malignant RT.
###end p 40
###begin p 41
###xml 117 122 117 122 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">INK4a</sup>
###xml 114 122 114 122 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p16<sup>INK4a</sup></italic>
###xml 197 202 197 202 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">INK4a</sup>
###xml 194 202 194 202 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p16<sup>INK4a</sup></italic>
###xml 230 235 230 235 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">INK4a</sup>
###xml 227 235 227 235 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p16<sup>INK4a</sup></italic>
###xml 383 387 383 387 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004482-Oruetxebarria1">[15]</xref>
###xml 389 393 389 393 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004482-Versteege2">[16]</xref>
###xml 395 399 395 399 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004482-Betz1">[29]</xref>
###xml 477 483 477 483 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN1A</italic>
###xml 631 635 631 635 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004482-Chai1">[14]</xref>
###xml 802 808 802 808 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN1A</italic>
###xml 920 924 920 924 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004482-Chai1">[14]</xref>
###xml 1160 1164 1160 1164 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004482-Versteege2">[16]</xref>
###xml 1400 1407 1400 1407 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMARCB1</italic>
Cell cycle regulators have been previously studied in RT cell lines. SMARCB1 is a transcriptional co-activator of p16INK4a and is required to bring the BRG1 chromatin remodelling complex to the p16INK4a promoter. Activation of p16INK4a inhibits the Cyclin D-CDK4 complex with the result that pRB is retained in its anti-proliferative hypo-phosphorylated state and cells arrest in G1 [15], [16], [29]. pRB is the critical endpoint for G1 arrest in RT. The CIP KIP family member CDKN1A is a critical effector of signal transduction pathways and has also previously been implicated as a downstream target for SMARCB1 in RT cell lines [14]. CIP KIP inhibitors bind and inhibit the kinase activity of CDK-cyclin complexes including Cyclin A-CDK2 and Cyclin E-CDK2 through a common shared N-terminal domain. CDKN1A is up-regulated following re-expression of SMARCB1, and expression is coincident with G1 arrest in these cells [14]. Cyclin E can overcome SMARCB1 induced proliferation arrest in RT cell lines also implying involvement of CIP KIP inhibitors in rhabdoid tumor, however in other studies CDKN1A and CDKN1B expression were unchanged by SMARCB1 expression [16]. We identified minor transcriptional upregulation of CDKN1A or CDKN1B in two different RT cell backgrounds following transfection with SMARCB1 however, expression of these genes persisted in clinical specimens of ATRT with inactivated SMARCB1 arguing against a major role in rhabdoid tumor aetiology.
###end p 41
###begin p 42
###xml 0 6 0 6 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN1C</italic>
###xml 48 54 48 54 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN1C</italic>
###xml 170 176 170 176 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN1C</italic>
###xml 267 271 267 271 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004482-Merlo1">[30]</xref>
###xml 273 279 273 279 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN1C</italic>
###xml 309 313 309 313 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004482-Cam1">[31]</xref>
###xml 453 459 453 459 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN1C</italic>
CDKN1C is a third member of the CIP KIP family. CDKN1C is regulated by p73 during mitotic exit and re-entry into G1 in T98G glioma cells and in myogenic differentiation, CDKN1C expression is induced by p73 and p63 to maintain pRB in an active hypophophorylated state [30]. CDKN1C is not transactivated by p53 [31]. Our results therefore suggest that SMARCB1 could be part of a pathway involving p73 or alternatively that SMARCB1 independently regulates CDKN1C. Due to a lack of suitable SMARCB1 antibodies for immunoprecipitation, we were unable to perform ChIP experiments to show whether SMARCB1 transactivated CDKN1C by direct promoter binding.
###end p 42
###begin p 43
###xml 236 240 236 240 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004482-Itoh1">[32]</xref>
###xml 242 246 242 246 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004482-Park1">[33]</xref>
###xml 425 429 425 429 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004482-Tsugu1">[34]</xref>
###xml 23 28 <span type="species:ncbi:9606">human</span>
###xml 280 285 <span type="species:ncbi:9606">human</span>
CDKN1C is expressed in human fetal brain and has been implicated in regulating the migration of neurons entering the neural plate and in the later stages of neurogenesis in driving the differentiation of oligodendrocyte precursor cells [32], [33]. CDKN1C is also not expressed in human astrocytomas however re-expression leads to a G1 block associated with hypophosphorylation of pRB, consistent with a tumor suppressor role [34]. Significantly and perhaps not surprisingly we found that CDKN1C expression was absent from the clinical tumor specimens we examined, of which the majority were CNS AT/RT, and our evidence from RT cell lines also supports an important role for CDKN1C in RT growth suppression.
###end p 43
###begin p 44
###xml 13 19 13 19 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN1C</italic>
###xml 118 122 118 122 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004482-Kikuchi1">[22]</xref>
###xml 166 172 166 172 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN1C</italic>
###xml 339 343 339 343 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004482-Shin1">[35]</xref>
###xml 367 373 367 373 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN1C</italic>
###xml 447 453 447 453 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN1C</italic>
###xml 512 516 512 516 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004482-Kuang1">[36]</xref>
###xml 595 598 595 598 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p73</italic>
###xml 600 603 600 603 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p15</italic>
###xml 608 614 608 614 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN1C</italic>
###xml 668 672 668 672 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004482-Shen1">[37]</xref>
###xml 699 705 699 705 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN1C</italic>
###xml 766 770 766 770 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004482-Kobatake1">[38]</xref>
###xml 833 839 833 839 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN1C</italic>
###xml 962 968 962 968 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN1C</italic>
###xml 1179 1185 1179 1185 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN1A</italic>
###xml 1190 1196 1190 1196 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN1B</italic>
###xml 1599 1605 1599 1605 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">cdkn1c</italic>
###xml 1656 1660 1656 1660 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004482-Umlauf1">[39]</xref>
###xml 639 647 <span type="species:ncbi:9606">patients</span>
###xml 1592 1598 <span type="species:ncbi:10090">murine</span>
Silencing of CDKN1C in cancer is usually epigenetic and associated with promoter methylation or histone deacetylation [22]. In gastric tumors both mechanisms silence CDKN1C and expression can be restored by demethylating reagents in cases where the promoter is hypermethylated or by HDACi in cases where promoter histones are deacetylated [35]. Growth suppression in CDKN1C-transduced leukaemia cell lines is dependent on the extent of endogenous CDKN1C promoter methylation within the recipient cell background [36]. Furthermore aberrant methylation of the cell cycle control pathway including p73, p15 and CDKN1C defines a subset of ALL patients with poor prognosis [37]. Evidence also exists for CDKN1C silencing in lung and breast cancer by promoter methylation [38]. Our results, showing increases in histone acetylation at the CDKN1C promoter in RT cell lines, following treatment of the cells with Romidepsin and following SMARCB1 induction, suggest that CDKN1C is epigenetically silenced in RT by histone deacetylation at the promoter, and that SMARCB1 is complexed with histone acetyl transferases or that it may have instrinsic acetylation properties. The promoters of CDKN1A and CDKN1B were not significantly affected by SMARCB1 induction and these genes exhibited minor changes in expression. In contrast, CDKN1C expression was markedly increased and this coincided with a specific increase in histone H3 acetylation and less marked increase in histone H4 acetylation. The predominant acetylation at histone H3 is consistent with studies showing that the transcriptionally active murine cdkn1c promoter is associated with acetylated histone H3 [39].
###end p 44
###begin p 45
###xml 0 6 0 6 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN1C</italic>
###xml 268 274 268 274 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN1C</italic>
###xml 366 372 366 372 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN1C</italic>
CDKN1C is a paternally imprinted gene and in most normal tissues is expressed from the maternal allele although frequently leaky expression also occurs from the paternal allele. SMARCB1 over-expression and HDACi did not universally induce monoallelic transcription of CDKN1C in all cell lines suggesting that SMARCB1 cannot be involved in establishing imprinting at CDKN1C, but that it is able to recognize and induce transcription from appropriately imprinted alleles. Significantly LIT1 methylation was normal in RT cell lines and in RT with loss of SMARCB1 function, demonstrating that loss of CDKN1C imprinting must involve mechanisms independent of IC2 on 11p15.5.
###end p 45
###begin p 46
###xml 0 6 0 6 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Cdkn1c</italic>
###xml 165 169 165 169 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004482-Andrews1">[40]</xref>
###xml 282 288 282 288 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN1C</italic>
###xml 327 330 327 330 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IC2</italic>
###xml 427 430 427 430 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IC2</italic>
###xml 516 520 516 520 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004482-Weksberg1">[41]</xref>
###xml 590 594 590 594 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004482-Jackson1">[42]</xref>
###xml 636 639 636 639 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IC2</italic>
###xml 725 732 725 732 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMARCB1</italic>
###xml 788 794 788 794 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN1C</italic>
###xml 884 890 884 890 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN1C</italic>
###xml 971 977 971 977 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN1C</italic>
###xml 1054 1061 1054 1061 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMARCB1</italic>
###xml 1167 1170 1167 1170 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004482-Taylor1">[5]</xref>
###xml 1172 1176 1172 1176 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004482-Modena1">[12]</xref>
###xml 1178 1182 1178 1182 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004482-Hulsebos1">[13]</xref>
###xml 1257 1264 1257 1264 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMARCB1</italic>
###xml 178 186 <span type="species:ncbi:9606">patients</span>
###xml 349 357 <span type="species:ncbi:9606">patients</span>
###xml 566 574 <span type="species:ncbi:9606">patients</span>
Cdkn1c has been recently shown to be a critical regulator of embryonic growth and is the only CIP KIP protein that is imprinted and essential for normal development [40]. 50% of patients with the overgrowth disorder Beckwith Wiedemann syndrome commonly have epigenetic silencing of CDKN1C caused by a methylation defect within IC2 on 11p15.5. These patients are at risk for cancer in early childhood. The spectrum of tumors in IC2 imprinting defect cases includes hepatoblastoma, rhabdomyosarcoma and gonadoblastoma [41] although these affect fewer than 5% of these patients. Jackson et al [42] recently reported a case with BWS and an IC2 defect with ATRT. However the ATRT also bore somatic loss of 22q and an inactivating SMARCB1 mutation, demonstrating that germ-line inactivation of CDKN1C was not sufficient to cause ATRT. This is consistent with the widespread inactivation of CDKN1C in many different cancers with additional oncogenic mutations and suggests that CDKN1C silencing contributes, but is alone insufficient, to cause tumors. Germline SMARCB1 mutations have been recently described in rare families with predisposition to RT and to schwannomatosis [5], [12], [13]. It might be expected that individuals carrying inactivating mutations in SMARCB1 in the germline might display phenotypic features in line with impaired CDKN1C expression such as high birth weight. However this has not been reported in the literature and too few cases have been identified to date to directly examine these associations.
###end p 46
###begin p 47
###xml 38 44 38 44 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN1C</italic>
###xml 233 239 233 239 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN1A</italic>
###xml 321 325 321 325 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004482-Lindemann1">[43]</xref>
###xml 342 348 342 348 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN1C</italic>
###xml 644 648 644 648 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004482-Andrews1">[40]</xref>
###xml 65 70 <span type="species:ncbi:9606">human</span>
###xml 812 817 <span type="species:ncbi:9606">human</span>
The fact that epigenetic silencing of CDKN1C is so widespread in human cancer makes it an attractive target for epigenetic therapies. To our knowledge it has not been previously identified as a target for Romidepsin. The promoter of CDKN1A is however frequently acetylated by HDACi and expression is induced (reviewed in [43]). The fact that CDKN1C is an imprinted gene makes it a more attractive target as its imprinted status provides an additional layer of developmental regulation and implies that comparatively small changes in expression in embryonic-like cells are likely to have potent effects on cell proliferation and differentiation [40]. In addition it has recently been shown to be a critical regulator of embryonic growth regulating through IGF1, a growth factor frequently abnormally expressed in human cancer.
###end p 47
###begin p 48
###xml 37 43 37 43 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN1C</italic>
###xml 204 210 204 210 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN1C</italic>
###xml 354 361 354 361 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMARCB1</italic>
###xml 398 404 398 404 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN1C</italic>
In summary we have demonstrated that CDKN1C is an important target for SMARCB1 and that RT cells are sensitive to small changes in CDKN1C expression. We show for the first time that SMARCB1 has a role in CDKN1C promoter histone acetylation suggesting opportunities for further investigation of signalling pathways that may be epigenetically regulated by SMARCB1. Furthermore as Romidepsin restores CDKN1C promoter histone acetylation, leading to increased CDKN1C expression, we propose that Romidepsin and related compounds could be further explored as therapeutic reagents in the treatment of RT through restoration of gene expression patterns lost as a result of SMARCB1 inactivation.
###end p 48
###begin title 49
Materials and Methods
###end title 49
###begin title 50
Cell lines and cell culture
###end title 50
###begin p 51
###xml 155 159 155 159 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004482-Ota1">[44]</xref>
###xml 161 165 161 165 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004482-Biegel2">[45]</xref>
###xml 292 293 286 287 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 295 302 289 296 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMARCB1</italic>
###xml 588 595 574 581 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMARCB1</italic>
###xml 600 606 586 592 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN1C</italic>
###xml 244 248 <span type="species:ncbi:9913">calf</span>
The G401 RT cell line was obtained from the American Type Culture Collection (ATCC). The establishment of STM91-01, BT16 and SJSC were previously reported [44], [45]. These RT cell lines were maintained in RPMI 1640 supplemented with 10% fetal calf serum (FCS) and grown at 37degreesC in 5%CO2. SMARCB1 recombinant STM91-01 cells were grown in the same media supplemented with 100 microg/mL hygromycin (Roche, Mannheim, Germany) and 1 microg/mL puromycin (Sigma Chemical Company, St. Louis, MO). G401 cells were maintained in McCoy's 5A modified media supplemented with 10% FCS, and both SMARCB1 and CDKN1C recombinant G401 clones were grown in the same media supplemented with 600 microg/mL geneticin (Invitrogen, Groningen, Netherlands) and 5 microg/mL puromycin (Sigma).
###end p 51
###begin p 52
Induction of SMARCB1 and CDKN1C in transformed cell lines was achieved by the addition of 1 microM 4-hydroxytamoxifen (4HT: Sigma Aldrich Castle Hill Australia). 4HT (1 mM) and Trichostatin A (TSA; Sigma Aldrich) (3.0 mM) were prepared in 100% ethanol. Romidepsin (10 mM)(Gloucester Pharmaceuticals) and 5-Aza-2'-deoxycytidine (5aza2dC; Sigma Aldrich) (2 mM) were prepared in 100% DMSO and stored in aliquots at -20degreesC. Appropriate dilutions were made into culture medium for experimental analyses. Relevant solvent controls were included in all experiments. Culture media and reagents were replaced every 24 hrs.
###end p 52
###begin p 53
###xml 90 91 90 91 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sup>
For imprinting and gene expression assays, cells were plated as replicate cultures at 2x105 cells/well in 2 ml culture volumes. Cells were trypsinized at 24 hourly time points, over a total time-course of 72 hours, washed in PBS, and pellets were frozen at -80degreesC for future RNA and DNA extraction.
###end p 53
###begin title 54
Southern blotting
###end title 54
###begin p 55
###xml 11 18 11 18 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMARCB1</italic>
###xml 342 343 342 343 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">R</sup>
###xml 552 554 546 548 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">32</sup>
###xml 577 584 571 578 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMARCB1</italic>
###xml 246 251 <span type="species:ncbi:9606">human</span>
To confirm SMARCB1 deletion or rearrangement in RT cell lines and in clinical specimens of rhabdoid tumor, 10 ug of RT cell line genomic DNA was digested with a panel of restriction enzymes and run overnight on 0.8% agarose gels alongside normal human genomic DNA as a control. DNA was transferred overnight in 20x SSC buffer onto Zeta Probe R GT Genomic tested blotting membrane (Biorad, Hercules CA 94547). Membranes were fixed under UV light, prehybridized at 60degreesC in ExpressHyb buffer (Clontech, Mountain View CA 94043) and hybridized with a 32P-labelled full length SMARCB1 PCR product, prepared by the random priming method, for 18 hours. Membranes were washed at room temperature with 2x SSC / 0.05% SDS for 40 mins and then with 0.1x SSC / 0.1% SDS for a further 40 mins at 55degreesC and exposed to phosphoimager screens for 24 to 48 hours. Bands were visualized with ImageQuant TL v2003.02 software following digital capture on a scanning phosphoimager (Molecular Dynamics).
###end p 55
###begin title 56
Cell cycle analysis
###end title 56
###begin p 57
###xml 4 5 4 5 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sup>
###xml 84 85 84 85 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sup>
###xml 167 171 167 171 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004482-Jordan1">[46]</xref>
###xml 186 187 186 187 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sup>
###xml 482 487 <span type="species:ncbi:10090">mouse</span>
###xml 493 498 <span type="species:ncbi:9606">human</span>
###xml 541 546 <span type="species:ncbi:10090">mouse</span>
5x105 cells were seeded and treated for 72 hrs. Media was replaced each 24 hrs. 5x105 cells were stained for cell cycle analysis using a modified flow cytometry assay [46]. Briefly, 5x105 cells were collected, washed in PBS/0.1% FCS, fixed with 1% formaldehyde (Polysciences, Warrington, PA) on ice for 30 mins, then permeabilized on ice with 0.5% Triton X-100 in PBS (Roche) for a further 15 mins. Cells were then incubated on ice in the dark for 45 mins with either PE-conjugated mouse anti-human Ki67 monoclonal antibody or PE-conjugated mouse IgG1 kappa monoclonal isotype control (BD Biosciences). After a final wash with PBS/0.1% FCS, cells were resuspended in 0.3 mL of washing buffer containing 1 microg/mL of 7-aminoactinomycin D (7AAD; Molecular Probes, Eugene, USA). Flow cytometric analysis was performed on a LSRII analyser (Becton Dickson) and data analysed using the FACS Diva software program. For each sample, electronic gating was performed on the intact, single cell population. Ki67 expression and 7AAD signal intensity were used to determine the cell cycle status of viable cells.
###end p 57
###begin title 58
Inducible expression system
###end title 58
###begin p 59
###xml 10 17 10 17 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMARCB1</italic>
###xml 111 118 111 118 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMARCB1</italic>
###xml 141 177 141 177 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-GGATCCACCATGATGATGATGGCGCTGAGC-3&#8242;</named-content>
###xml 197 234 197 234 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-GCCTCGAGTTACCAGGCCGGGGCCGTGTTGG-3&#8242;</named-content>
###xml 795 802 795 802 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMARCB1</italic>
###xml 933 940 933 940 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMARCB1</italic>
###xml 1030 1036 1030 1036 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN1C</italic>
###xml 1163 1199 1163 1199 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242; GCGGTACCACCATGTCCGACGCGTCCCTCC-3&#8242;</named-content>
###xml 1219 1251 1219 1251 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-GCGGATCCTCACCGCAGCCTCTTGCG-3&#8242;</named-content>
###xml 1465 1472 1465 1472 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMARCB1</italic>
###xml 4 9 <span type="species:ncbi:9606">human</span>
###xml 105 110 <span type="species:ncbi:9606">human</span>
###xml 1024 1029 <span type="species:ncbi:9606">human</span>
The human SMARCB1 coding sequence was PCR amplified from plasmid (PCR4-TOPO-INI1) containing full-length human SMARCB1, using forward primer 5'-GGATCCACCATGATGATGATGGCGCTGAGC-3' and reverse primer 5'-GCCTCGAGTTACCAGGCCGGGGCCGTGTTGG-3' containing BamH1 and Xho1 restriction sites respectively. The PCR product was digested with BamH1 and Xho1 and inserted into the vector pcDNA3 UAS/neo (kindly provided by Dr.J.Silke, La Trobe University, Victoria, Australia ). The integrity of the construct was verified by direct automated sequencing. The vector was linearized and then co-transfected with a second linearized vector, pEF puro/GEV, into G401 cells. Transfection was achieved using Lipofectamine 2000 (Invitrogen) according to the manufacturer's instructions. Cells containing both pcDNA3 UAS SMARCB1 and pEF puro/GEV were doubly selected in geneticin and puromycin. Single cells were selected and grown and clones were tested for SMARCB1 expression by Western blotting following the addition of 1 uM 4HT. The full length human CDKN1C coding sequence was PCR amplified from plasmid (pCMV6-XL4 CDKN1C) (Origene Technologies, Rockville, MD), using forward primer 5' GCGGTACCACCATGTCCGACGCGTCCCTCC-3' and reverse primer 5'-GCGGATCCTCACCGCAGCCTCTTGCG-3' containing Kpn1 and BamH1 restriction sites respectively. The PCR product was digested with Kpn1 and BamH1 and inserted into the vector pcDNA3 UAS/neo. Transfection and selection in G401 cells was the same as for SMARCB1 and clones were tested for CDKN1C expression by western blotting following the addition of 1 uM 4HT.
###end p 59
###begin title 60
Lentiviral production and transfection
###end title 60
###begin p 61
###xml 170 174 170 174 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004482-Dunning1">[47]</xref>
The STM91-01 cell line was found to be refractory to transfection using the above vector system and a lentiviral system was used to produce pooled recombinant cell lines [47].
###end p 61
###begin p 62
###xml 10 17 10 17 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMARCB1</italic>
###xml 194 231 194 231 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-GCTCTAGATTACCAGGCCGGGGCCGTGTTGG-3&#8242;</named-content>
###xml 4 9 <span type="species:ncbi:9606">human</span>
The human SMARCB1 coding sequence was amplified and cloned into the BamHI and XbaI sites of the vector, pF 5xUAS Sv40 puro, using the same forward primer as above and a modified reverse primer, 5'-GCTCTAGATTACCAGGCCGGGGCCGTGTTGG-3'. HEK 293T cells were transiently transfected with pF 5xUAS Sv40 puro containing SMARCB1or pF GEV16 hygro vector with the packaging vectors pCMVdeltaR8.2 and VSVG, using Effectene (Qiagen, Hilden Germany) as described by the manufacturer. The media was changed after 16 hrs and virus-containing supernatant was collected after 48 hours, filtered through 0.45 microm Millipore filters, and frozen at -80degreesC.
###end p 62
###begin p 63
###xml 40 41 40 41 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 336 337 314 315 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
For transduction in STM91-01 cells, 1x106 of the target cells were washed in PBS and then incubated in virus-containing media containing 5 microg/mL polybrene (Sigma Aldrich) in 6-well plates. Plates were then spun at 2500 rpm for 90 mins at 30degreesC, incubated for a further 90 mins at 30degreesC, then returned to 37degreesC in 5%CO2. Media was changed the next day and 2 days after transduction the appropriate selection was added. First, cells were infected with pF GEV16 hygro virus and selected in hygromycin. Hygromycin resistant cells were then infected with pF 5xUAS Sv40 puro/ini1 virus followed by selection in puromycin. A pool of resistant cells was then tested for SMARCB1 expression by western blotting following the addition of 1 uM 4HT.
###end p 63
###begin title 64
siRNA transfection
###end title 64
###begin p 65
###xml 1638 1639 1624 1625 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">0</sub>
Optimal transfection conditions for G401 F22 cells were determined using BLOCK-iT fluorescent oligo (Invitrogen). Cells were plated at optimal density for the culture plate used and allowed to adhere overnight. ON-TARGETplus SMARTpool CDKN1C siRNA (Dharmacon, CO, USA) was transfected at a final concentration of 10 nM in the presence of 3 microg/mL DharmaFECT2 transfection reagent (Dharmacon) according to the manufacturer's instructions. Additionally, ON-TARGETplus siCONTROL Non-targeting pool (Dharmacon) was transfected in the same manner as a control (mock) transfection. 6 hrs after transfection, 1 microM 4HT or ethanol control was added to induce SMARCB1 expression. Media was refreshed every 24 hrs, maintaining 1 uM 4HT or ETOH, as required, with 1 nM oligo. Cells were harvested at 24 hr intervals for RNA extraction and for determination of cell proliferation by the MTS assay. CDKN1C expression was examined as described under "Gene expression and imprinting". Cell proliferation was measured by the MTS-based CellTiter 96 Aqueous non-radioactive cell proliferation assay (Promega, WI, USA). Briefly, triplicate wells of siRNA transfected cells, induced or un-induced for SMARCB1, were incubated with [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt] (MTS)/phenazine methosulfate (PMS) solution for 2 hrs at 37degreesC. Well absorbance was measured at 492 nm and a reference wavelength of 620 nm using a Multiskan ES spectrophotometer (Thermo Electron, ON, Canada) at 24 hourly time intervals. The absorbance at each time interval was normalized in each culture to the t0 absorbance value, which was set to 1.0. Absorbance differences in each 24 hour interval, reflecting the rate of proliferation in individual cultures, were calculated by subtraction of normalized absorbance values.
###end p 65
###begin title 66
Western blotting
###end title 66
###begin p 67
###xml 37 38 37 38 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sup>
###xml 1149 1154 <span type="species:ncbi:10090">mouse</span>
###xml 1204 1208 <span type="species:ncbi:9925">goat</span>
Cell pellets containing at least 2x105 cells were lysed in mammalian lysis buffer (50 mM Tris, pH 7.5; 375 mM NaCl; 1 mM ethylenediamine tetraacetic acid; 1% Triton X-100) and then sonicated to shear DNA. Total protein was determined using the Bicinchoninic (BCA) protein assay (Sigma Aldrich) according to the manufacturer's instructions. Twenty micrograms of protein were separated on 12% sodium dodecyl sulfate-polyacrylamide gels, transferred onto Hybond-P nitrocellulose membrane (Amersham, Buckinghamshire, England), blocked with 5% non-fat dry milk in phosphate-buffered saline (PBS), and probed with the indicated antibodies in 5% non-fat dry milk in PBS with 0.05% Tween-20. HRP-conjugated antibodies were detected using Super-Signal(R) West Dura Extended Duration Substrate (Pierce, Rockford, IL) and exposing to film (Hyperfilm MP, Amersham). The following antibodies were used for immunoblotting: BAF47 (BD Pharmingen, San Diego, CA) detecting SMARCB1, beta-actin (Sigma Aldrich, p57 (C20) (Santa Cruz Biotech, Santa Cruz, CA) or p57 Kip2 (Cell Signaling Technology, Danvers MA USA) detecting CDKN1C, beta-actin (Sigma Aldrich), an anti-mouse immunoglobulin-G HRP (Sigma Aldrich) and an anti-goat immunoglobulin-G HRP (Sigma Aldrich) secondary antibody.
###end p 67
###begin title 68
Gene expression and imprinting
###end title 68
###begin p 69
###xml 72 73 72 73 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sup>
###xml 174 180 174 180 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN1C</italic>
###xml 193 217 193 217 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242; GCGTTCTACCGCGAGACG 3&#8242;</named-content>
###xml 227 254 227 254 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242; CGAGTGCAGCTGGTCAGCGAG 3&#8242;</named-content>
###xml 647 651 647 651 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004482-Algar2">[26]</xref>
Genomic DNA was extracted from RT cell pellets, comprising at least 2x105 cells, using the DNeasy Blood and Tissue kit (Qiagen) according to the manufacturer's instructions. CDKN1C primers F4 (5' GCGTTCTACCGCGAGACG 3') and R5 (5' CGAGTGCAGCTGGTCAGCGAG 3') were used to amplify across the region of deletion polymorphisms in exon 1 using the Enhancer PCR system (Invitrogen Corporation CA 92006) and Hi Fi Taq polymerase (Roche, Mannheim, Germany). PCR products were digested with PvuII and separated on 6% non-denaturing polyacryamide gels containing 10% glycerol to identify polymorphisms required for imprinting analysis as previously described [26]. Bands were visualised by staining with ethidium bromide and digital images were captured following UV exposure on a Biorad Gel Doc 1000 system. PCR products were sequenced using Big Dye terminator technology to determine allele sizes.
###end p 69
###begin p 70
###xml 63 64 63 64 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sup>
###xml 353 380 353 380 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;GCAGCTGCCTAGTGTCCCGGTC 3&#8242;</named-content>
###xml 400 427 400 427 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242; TAAAT TGGCTCACCGCAGCC 3&#8242;</named-content>
RNA was extracted from RT cell pellets comprising at least 2x105 cells, using the RNeasy Mini kit (Qiagen) according to the manufacturer's instructions. 1 ug of RNA was reverse transcribed with random primers (pd(N)6) (Amersham Pharmacia Biotech) and M-MLV Reverse Transcriptase RNaseH minus (Promega Corporation). CDKN1C was amplified with primers F2 (5'GCAGCTGCCTAGTGTCCCGGTC 3') in exon 1 and R7 (5' TAAAT TGGCTCACCGCAGCC 3') spanning exons 2 and 3 within the 3'UTR using the Enhancer PCR system with Hi Fi Taq polymerase. Cycling was 95degreesC for 3 mins, 45 cycles of 95degreesC for 45 secs, 56degreesC for 30 secs, 68degreesC for 1 min 30 secs and a final extensions step at 68degreesC for 10 mins. PCR products were digested with PvuII and electrophoresed as described above.
###end p 70
###begin p 71
###xml 0 6 0 6 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN1A</italic>
###xml 46 73 46 73 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242; GAGGCACCGAGGCACTCAGAG 3&#8242;</named-content>
###xml 85 111 85 111 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242; GGCACAAGGGTACAAGACAG 3&#8242;</named-content>
###xml 248 254 248 254 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN1B</italic>
###xml 294 321 294 321 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242; CCATGTCAAACGTGCGAGTGT 3&#8242;</named-content>
###xml 333 358 333 358 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242; CGTTTGACGTCTTCTGAGG 3&#8242;</named-content>
###xml 391 397 391 397 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN1B</italic>
###xml 454 460 454 460 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN1A</italic>
###xml 465 471 465 471 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN1B</italic>
CDKN1A (p21) was amplified with primers p21F (5' GAGGCACCGAGGCACTCAGAG 3') and p21R (5' GGCACAAGGGTACAAGACAG 3') using Go Taq Green master mix (Promega Corporation). Primers were located in exon 1 and 2 respectively to ensure specificity for cDNA. CDKN1B (p27) was amplified with primers p27F (5' CCATGTCAAACGTGCGAGTGT 3') and p27R (5' CGTTTGACGTCTTCTGAGG 3') using Go Taq Green master mix. CDKN1B primers were located in separate exons. PCR cycling for CDKN1A and CDKN1B was at 94degreesC for 5 minutes, 94degreesC 30 secs, 55degreesC for 30 secs, 72degreesC for 30 secs for at least 28 cycles, followed by a final step at 72degreesC for 5 minutes.
###end p 71
###begin p 72
###xml 125 129 125 129 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004482-Niemitz1">[48]</xref>
###xml 152 176 152 176 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242; GCGGCGATCAAGAAGCTG 3&#8242;</named-content>
###xml 191 215 191 215 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242; CGACGACTTCTCAGGCGC 3&#8242;</named-content>
###xml 241 274 241 274 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242; CTCTGATCTCCGATTTCTTCGCCAAGC 3&#8242;</named-content>
Real-time Q-PCR for CDKN1C expression was performed using the primer and Taqman probe combination described in Niemitz et al [48]. These were p57 1044F 5' GCGGCGATCAAGAAGCTG 3' and p57 1124R 5' CGACGACTTCTCAGGCGC 3' with probe p57 1069T FAM 5' CTCTGATCTCCGATTTCTTCGCCAAGC 3' TAMRA. Reactions were performed using a Quantitect Probe PCR probe mastermix (Qiagen) and run in triplicate on a Rotorgene 3000 real-time thermal cycler (Corbett Technologies, Sydney Australia). Reaction tubes were set up using the CAS1200 robotic system of Corbett Technologies. Data was analysed using the Rotorgene's comparative quantitation software using selected untreated samples as the calibrator. Expression of the housekeeping gene, glucuronidase beta (GUSB), was examined by Q-PCR using the Quantitect Probe PCR kit (Qiagen) according to the manufacturer's instructions. Reactions were set up and performed in triplicate as for CDKN1C. Data was analysed using comparative quantitation software and untreated samples were used as the calibrator as for CDKN1C. CDKN1C data was normalized to GUSB to derive relative changes in CDKN1C expression. Levels of GUSB remained stable in all reactions, however after 48 hours of treatment with 10 nM Romidepsin, GUSB levels were noted to decline in the RT cell lines.
###end p 72
###begin title 73
Methylation analysis and Chromatin Immunoprecipitation
###end title 73
###begin p 74
###xml 15 19 15 19 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LIT1</italic>
###xml 232 236 232 236 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004482-Smilinich1">[27]</xref>
Methylation at LIT1 (OMIM 604115) was examined by southern blotting following digestion of 5 ug of DNA with EcoRI and NotI. Southern blots were probed with the probe DMRP recognizing a 4.2 kb methylated and 2.7 kb unmethylated band [27]. Prehybridization, hybridization and washing steps were as described for southern blotting above. Bands were visualized and quantified with ImageQuant TL v2003.02 software following digital capture on a scanning phosphoimager (Molecular Dynamics). The methylation index was calculated as the peak volume of the methylated band divided by the sum of the volumes of the methylated and unmethylated bands after background subtraction.
###end p 74
###begin p 75
###xml 23 29 23 29 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN1C</italic>
###xml 315 342 306 333 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242; GGTTGGGYGTTTTATAGGTTA 3&#8242;</named-content>
###xml 354 387 345 378 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242; ACCTAACTATCCGATAATAAACTCTTC 3&#8242;</named-content>
###xml 530 534 521 525 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004482-Kikuchi1">[22]</xref>
###xml 865 866 847 848 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">R</sup>
###xml 213 218 <span type="species:ncbi:9606">Human</span>
Methylation within the CDKN1C promoter was analysed by sequencing bisulphite-modified DNA.1 ug of DNA extracted from RT cells was bisulphite modified using the MethyEasytrade mark DNA Bisulphite Modification Kit (Human Genetic Signatures Pty Ltd NSW Australia). Modified DNA easy was amplified using primers p57-CF 5' GGTTGGGYGTTTTATAGGTTA 3' and p57-CR 5' ACCTAACTATCCGATAATAAACTCTTC 3' generating a 155 bp product derived from the region across the CDKN1C transcription start site from -41 to +114 as described in Kikuchi et al [22]. The amplified product was then cloned into the PCR-Script Amp cloning vector (Stratagene, La Jolla CA). Cloning and transformation were performed as recommended in the PCR-Scripttrade mark Amp Cloning kit (Stratagene). Selected blue colonies were grown in liquid media and plasmid DNA was extracted and purified using the QIAprepR Spin Miniprep Kit (Qiagen). Plasmid DNA was sequenced using Big Dye terminator technology (Applied Biosystems) according to the manufacturer's instructions using vector primer T7. At least ten plasmids each were sequenced from un-induced and 4HT-induced RT cultures.
###end p 75
###begin p 76
###xml 555 561 546 552 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN1C</italic>
###xml 633 637 624 628 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004482-Kikuchi1">[22]</xref>
###xml 663 693 654 684 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242; GTATAAAGGGGGCGCAGGCGGGCT 3&#8242;</named-content>
###xml 709 740 700 731 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242; TGGTGGACTCTTCTGCGTCGGGTTC 3&#8242;</named-content>
###xml 866 867 857 858 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1196 1224 1157 1185 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242; TCGGTGCGTGCCCAGTTGAACC 3&#8242;</named-content>
###xml 1241 1271 1202 1232 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242; ATGCGGCTGACTGTCGAACAGGAG 3&#8242;</named-content>
###xml 1783 1789 1744 1750 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN1A</italic>
###xml 1794 1800 1755 1761 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN1B</italic>
###xml 1869 1875 1830 1836 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN1A</italic>
###xml 1918 1922 1879 1883 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004482-Takai1">[49]</xref>
###xml 1927 1933 1888 1894 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN1B</italic>
###xml 1973 1977 1934 1938 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004482-Li1">[50]</xref>
###xml 2000 2026 1961 1987 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5 &#8242;GGTGTCTAGGTGCTCCAGGT 3&#8242;</named-content>
###xml 2041 2067 2002 2028 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242; GCACTCTCCAGGAGGACACA 3&#8242;</named-content>
###xml 2096 2122 2057 2083 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242; GTCCCTTCCAGCTGTCACAT 3&#8242;</named-content>
###xml 2137 2163 2098 2124 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242; GGAAACCAACCTTCCGTTCT 3&#8242;</named-content>
###xml 2268 2269 2229 2230 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
Chromatin immunoprecipitation was performed exactly as described in the protocols provided with the Acetyl-Histone H4 and H3 Immunoprecipitation (ChIP) assay kits (Upstate cell signalling solutions Temecula CA 92590). Sonication was performed by pulsing three times for 10 seconds at 30% power, using a Vibra Celltrade mark ultrasonic processor (SONICS). Sheared DNA was examined on 1% agarose gels. DNA bound to immunoprecipitated histone was recovered by phenol/chloroform extraction and ethanol precipitation.PCR on ChIP'd DNA was performed across the CDKN1C transcription start site from -72 to +89 as described in Kikuchi et al [22]. Primers were p57 ChIP F 5' GTATAAAGGGGGCGCAGGCGGGCT 3' and p57 ChIP R 5' TGGTGGACTCTTCTGCGTCGGGTTC 3' (product 161 bp). 2 uL of DNA was amplified in a reaction volume of 25 uL containing 1x Sybr Green, 1x Sensimix, 0.25 mM MgCl2, and 10 picomoles of each primer as per the recommendations in the 2x Sensimix DNA kit (Quantace, London). Cycling was 95degreesC for 10 mins, 45 cycles of 95degreesC for 15 secs, 62degreesC for 15 secs, 72degreesC for 20 secs followed by a melt step ramping from 72 to 95degreesC. GAPDH was amplified using primers GAPDH ChIPF 5' TCGGTGCGTGCCCAGTTGAACC 3' and GAPDH ChIPR 5' ATGCGGCTGACTGTCGAACAGGAG 3' (product 246 bp) under the same conditions. Reactions were set up in triplicate for each sample on a CAS1200 robotic system and run on a Rotorgene 3000 real-time thermal cycler (Corbett Technologies). Reaction conditions were designed to eliminate primer dimer formation. The comparative quantitation option in the Rotorgene software was used to analyse the data. A normal control DNA sample run in triplicate was used as the calibrator for both CDKN1C and GAPDH. CDKN1C/GAPDH ratios were derived for each run. CDKN1A and CDKN1B promoters in ChIP fractions were examined in a similar manner using CDKN1A promoter primers described in Takai et al [49] and CDKN1B promoter primers described in Li et al [50]. These were p21F PROM 5 'GGTGTCTAGGTGCTCCAGGT 3' and p21R PROM 5' GCACTCTCCAGGAGGACACA 3' (product 255 bp), p27F PROM 5' GTCCCTTCCAGCTGTCACAT 3' and p27R PROM 5' GGAAACCAACCTTCCGTTCT 3' (product 162 bp). Sensimix reaction mixes were as described for CDKN1C and GAPDH however additional MgCl2 was not added. CDKN1A cycling was 95degreesC for 10 mins, 45 cycles of 95degreesC for 15 secs, 61degreesC for 15 secs, 72degreesC for 20 secs followed by a melt step ramping from 72degreesC to 95degreesC. CDKN1B cycling was 95degreesC for 10 mins, 45 cycles of 95degreesC for 15 secs, 57degreesC for 15 secs, 72degreesC for 20 secs followed by a melt step ramping from 72degreesC to 95degreesC. Reaction conditions were designed to eliminate primer dimer formation.
###end p 76
###begin title 77
Tissues and mutation screening in ATRT
###end title 77
###begin p 78
###xml 112 119 112 119 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMARCB1</italic>
###xml 160 164 160 164 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004482-Judkins1">[51]</xref>
###xml 771 778 771 778 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D22S303</italic>
###xml 780 787 780 787 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D22S257</italic>
###xml 789 796 789 796 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D22S301</italic>
###xml 798 805 798 805 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D22S345</italic>
###xml 807 815 807 815 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D22S1685</italic>
###xml 820 826 820 826 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TOPIP2</italic>
Specimens with a clinical diagnosis of RT were submitted to the laboratory for molecular diagnostic testing for SMARCB1 mutation, or absence of SMARCB1 protein [51], after obtaining informed consent. Analysis of clinical samples was approved by the institutional ethics committee under approval number RCH HREC 24073A. RNA was extracted from frozen sections using the RNeasy mini kit (Qiagen) and DNA was extracted from either frozen sections or formalin-fixed tissue using protocols described in the DNeasy Blood and Tissue kit (Qiagen). cDNA was prepared in a total volume of 40 uL from 1 ug RNA as described above for RT cell lines. Allele loss studies were performed using microsatellite markers mapping to 22q, on both blood and tumor DNA. Markers analysed included D22S303, D22S257, D22S301, D22S345, D22S1685 and TOPIP2. Alleles were examined by PCR amplification of 50-100 ng DNA using primers end-labelled with Fam, Hex or Tet. PCR products were electrophoresed on 4.5% 0.2 mm denaturing polyacrylamide gels on an ABI 377 DNA sequencer employing TAMRA 500 (Red) size standard. Sample lanes were tracked with Genescan software Version 3.1.2 and analysed using Genotyper Version 2.1. Mutation screening was performed by direct DNA sequencing of PCR products. Primers were located in introns flanking individual exons and were designed to amplify exonic and flanking splice site sequences. Exon 1 was divided into two separate overlapping fragments for PCR. Primer sequences and reaction conditions are available on request. Sequence analysis was performed by both manual inspection and with Mutation Surveyor (Softgenetics PA 16803). BLAST analysis was performed against genome databases.
###end p 78
###begin title 79
Immunohistochemistry
###end title 79
###begin p 80
###xml 303 307 303 307 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004482-Judkins1">[51]</xref>
###xml 309 313 309 313 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004482-Merchant1">[52]</xref>
Immunohistochemical stains were performed on representative formalin-fixed paraffin-embedded tissue sections of a thickness of 2 micron using the monoclonal antibodies INI-1/BAF-47 (clone 25/BAF47, 1:10, BD Biosciences, North Ryde, Australia) and p57/KIP2 (clone 25B2, 1:200, Novocastra, Newcastle, UK) [51], [52]. Heat-induced antigen retrieval was performed for 20 minutes at 100degreesC at pH 6.0 and 9.0, respectively, using target retrieval solution (Dako, Copenhagen, Denmark). The detection system used was standard streptavidin-biotin peroxidase complex (DAKO, Copenhagen, Denmark) with diaminobenzidine as the chromogen. The slides were counterstained with haematoxylin.
###end p 80
###begin title 81
Supporting Information
###end title 81
###begin p 82
Cell cycle effects of SMARCB1 and CDKN1C. A. Cell cycle analysis in control cultures and in cultures induced to express SMARCB1. The data represents the mean from three independent experiments and the error bars represent the standard error of the mean. B. Cell cycle analysis in control cultures and in cultures induced to express CDKN1C. The data represents the mean from three independent experiments and the error bars represent the standard error of the mean.
###end p 82
###begin p 83
(0.21 MB TIF)
###end p 83
###begin p 84
Click here for additional data file.
###end p 84
###begin p 85
CDKN1C promoter methylation analysis. Allelic bisulphite sequence analysis at the CDKN1C promoter in uninduced (-4HT) and in induced (+4HT) F22 and STMpc cells. Open circles represent unmethylated cytosines and filled circles represent methylated cytosines. No significant change in allelic methylation was identified following the induction of SMARCB1 protein expression.
###end p 85
###begin p 86
(0.52 MB TIF)
###end p 86
###begin p 87
Click here for additional data file.
###end p 87
###begin p 88
CDKN1C shows loss of imprinting in rhabdoid tumor. CDKN1C imprinting in G401 and STM91-01 rhabdoid tumor cell lines after 24, 48 and 72 hours in culture. CDKN1C alleles in G401 cells differed by 24 bp and those in STM91-01 differed by 12 bp.
###end p 88
###begin p 89
(0.08 MB TIF)
###end p 89
###begin p 90
Click here for additional data file.
###end p 90
###begin p 91
Normal LIT1 methylation is maintained in rhabdoid tumor. Methylation sensitive southern blotting at IC2 (LIT1) in G401 and STM91-01 cells showing normal patterns of methylation, with methylated (4.2 kb) and unmethylated (2.7 kb) bands of similar intensity.
###end p 91
###begin p 92
(0.06 MB TIF)
###end p 92
###begin p 93
Click here for additional data file.
###end p 93
###begin p 94
###xml 173 180 173 180 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0004482-t001">Table 1</xref>
CDKN1C expression in clinical specimens of rhabdoid tumor. A. Gene expression examined by RT-PCR in clinical specimens of rhabdoid tumor. Tumor numbers match those shown in Table 1. Relevant controls are shown: The -ve lane represents the PCR negative control, the RNA -ve control lane represents the negative control for reverse transcription and the RT-ve control represents a control for genomic contamination derived from the induced F22 sample. The positive control in the far right lane shows the level of gene expression in F22 cells expressing SMARCB1. Viability of the cDNA is shown by amplification of the HPRT control gene. The lane for sample 3180 shows that little viable cDNA was obtained from this sample as indicated by the negligible level of HPRT gene expression. B. Immunohistochemical stains for CDKN1C expression. 1) placenta positive control showing strong nuclear staining for CDKN1C, 2) endometrium negative control, 3) placenta without primary antibody 4) tumor section from case 1993 and 5) tumor section from case 1938. 1993 and 1938 show some cytoplasmic staining for CDKN1C but no nuclear staining.
###end p 94
###begin p 95
(0.71 MB TIF)
###end p 95
###begin p 96
Click here for additional data file.
###end p 96
###begin p 97
Romidepsin reduces proliferation in rhabdoid tumor cells. Table showing the percentage of cells in each cell cycle phase after 72 hours treatment with 1 nM Romidepsin and in controls containing 0.01% DMSO. The G401 data represent the mean values from three independent experiments and the STM91-01 data represent the mean values from six independent experiments. The error represents the standard error of the mean.
###end p 97
###begin p 98
(0.03 MB DOC)
###end p 98
###begin p 99
Click here for additional data file.
###end p 99
###begin p 100
###xml 51 59 <span type="species:ncbi:9606">Children</span>
We acknowledge the contributions of CIKA (AM), the Children's Cancer Centre Foundation (EA), My Room (VD), the NIH (CA46274 to JAB) and NHMRC (PGE).
###end p 100
###begin title 101
References
###end title 101
###begin article-title 102
Truncating mutations of hSNF5/INI1 in aggressive paediatric cancer.
###end article-title 102
###begin article-title 103
Alterations of the hSNF5/INI1 gene in central nervous system atypical teratoid/rhabdoid tumors and renal and extrarenal rhabdoid tumors.
###end article-title 103
###begin article-title 104
Mutations of the hSNF5/INI1 gene in renal rhabdoid tumors with second primary brain tumors.
###end article-title 104
###begin article-title 105
###xml 44 49 <span type="species:ncbi:9606">human</span>
Spectrum of hSNF5/INI1 somatic mutations in human cancer and genotype-phenotype correlations.
###end article-title 105
###begin article-title 106
Familial posterior fossa brain tumors of infancy secondary to germline mutation of the hSNF5 gene.
###end article-title 106
###begin article-title 107
hSNF5/INI1 inactivation is mainly associated with homozygous deletions and mitotic recombinations in rhabdoid tumors.
###end article-title 107
###begin article-title 108
###xml 77 81 <span type="species:ncbi:10090">mice</span>
Disruption of Ini1 leads to peri-implantation lethality and tumorigenesis in mice.
###end article-title 108
###begin article-title 109
###xml 4 10 <span type="species:ncbi:10090">murine</span>
The murine SNF5/INI1 chromatin remodeling factor is essential for embryonic development and tumor suppression.
###end article-title 109
###begin article-title 110
###xml 96 100 <span type="species:ncbi:10090">mice</span>
Haploinsufficiency of Snf5 (integrase interactor 1) predisposes to malignant rhabdoid tumors in mice.
###end article-title 110
###begin article-title 111
Highly penetrant, rapid tumorigenesis through conditional inversion of the tumor suppressor gene Snf5.
###end article-title 111
###begin article-title 112
Increased DNA damage sensitivity and apoptosis in cells lacking the Snf5/Ini1 subunit of the SWI/SNF chromatin remodeling complex.
###end article-title 112
###begin article-title 113
SMARCB1/INI1 tumor suppressor gene is frequently inactivated in epithelioid sarcomas.
###end article-title 113
###begin article-title 114
Germline mutation of INI1/SMARCB1 in familial schwannomatosis.
###end article-title 114
###begin article-title 115
Loss of the hSNF5 gene concomitantly inactivates p21CIP/WAF1 and p16INK4a activity associated with replicative senescence in A204 rhabdoid tumor cells.
###end article-title 115
###begin article-title 116
P16INK4a is required for hSNF5 chromatin remodeler-induced cellular senescence in malignant rhabdoid tumor cells.
###end article-title 116
###begin article-title 117
A key role of the hSNF5/INI1 tumour suppressor in the control of the G1-S transition of the cell cycle.
###end article-title 117
###begin article-title 118
Loss of the INI1 tumor suppressor does not impair the expression of multiple BRG1-dependent genes or the assembly of SWI/SNF enzymes.
###end article-title 118
###begin article-title 119
SWI/SNF chromatin-remodeling factors induce changes in DNA methylation to promote transcriptional activation.
###end article-title 119
###begin article-title 120
INI1/hSNF5/BAF47 represses c-fos transcription via a histone deacetylase-dependent manner.
###end article-title 120
###begin article-title 121
Cell cycle arrest and repression of cyclin D1 transcription by INI1/hSNF5.
###end article-title 121
###begin article-title 122
INI1 expression induces cell cycle arrest and markers of senescence in malignant rhabdoid tumor cells.
###end article-title 122
###begin article-title 123
###xml 91 96 <span type="species:ncbi:9606">human</span>
Inactivation of p57KIP2 by regional promoter hypermethylation and histone deacetylation in human tumors.
###end article-title 123
###begin article-title 124
Epigenetic and chromatin modifiers as targeted therapy of hematologic malignancies.
###end article-title 124
###begin article-title 125
###xml 34 39 <span type="species:ncbi:9606">human</span>
Imprinting of the gene encoding a human cyclin-dependent kinase inhibitor, p57KIP2, on chromosome 11p15.
###end article-title 125
###begin article-title 126
Analysis of CDKN1C in Beckwith Wiedemann syndrome.
###end article-title 126
###begin article-title 127
###xml 49 57 <span type="species:ncbi:9606">patients</span>
CDKN1C expression in Beckwith-Wiedemann syndrome patients with allele imbalance.
###end article-title 127
###begin article-title 128
A maternally methylated CpG island in KvLQT1 is associated with an antisense paternal transcript and loss of imprinting in Beckwith-Wiedemann syndrome.
###end article-title 128
###begin article-title 129
Silencing of CDKN1C (p57KIP2) is associated with hypomethylation at KvDMR1 in Beckwith-Wiedemann syndrome.
###end article-title 129
###begin article-title 130
Re-expression of hSNF5/INI1/BAF47 in pediatric tumor cells leads to G1 arrest associated with induction of p16ink4a and activation of RB.
###end article-title 130
###begin article-title 131
A role of p73 in mitotic exit.
###end article-title 131
###begin article-title 132
p53 family members in myogenic differentiation and rhabdomyosarcoma development.
###end article-title 132
###begin article-title 133
###xml 97 102 <span type="species:ncbi:10090">mouse</span>
The cyclin-dependent kinase inhibitors p57 and p27 regulate neuronal migration in the developing mouse neocortex.
###end article-title 133
###begin article-title 134
###xml 33 42 <span type="species:ncbi:7955">zebrafish</span>
Oligodendrocyte specification in zebrafish requires notch-regulated cyclin-dependent kinase inhibitor function.
###end article-title 134
###begin article-title 135
###xml 54 59 <span type="species:ncbi:9606">human</span>
Expression of p57(KIP2) potently blocks the growth of human astrocytomas and induces cell senescence.
###end article-title 135
###begin article-title 136
Mechanism for inactivation of the KIP family cyclin-dependent kinase inhibitor genes in gastric cancer cells.
###end article-title 136
###begin article-title 137
Differential tumor suppressor properties and transforming growth factor-beta responsiveness of p57KIP2 in leukemia cells with aberrant p57KIP2 promoter DNA methylation.
###end article-title 137
###begin article-title 138
Aberrant DNA methylation of p57KIP2 identifies a cell-cycle regulatory pathway with prognostic impact in adult acute lymphocytic leukemia.
###end article-title 138
###begin article-title 139
Aberrant methylation of p57KIP2 gene in lung and breast cancers and malignant mesotheliomas.
###end article-title 139
###begin article-title 140
###xml 37 42 <span type="species:ncbi:10090">mouse</span>
Imprinting along the Kcnq1 domain on mouse chromosome 7 involves repressive histone methylation and recruitment of Polycomb group complexes.
###end article-title 140
###begin article-title 141
###xml 91 96 <span type="species:ncbi:10090">mouse</span>
Cdkn1c (p57Kip2) is the major regulator of embryonic growth within its imprinted domain on mouse distal chromosome 7.
###end article-title 141
###begin article-title 142
Tumor development in the Beckwith-Wiedemann syndrome is associated with a variety of constitutional molecular 11p15 alterations including imprinting defects of KCNQ1OT1.
###end article-title 142
###begin article-title 143
###xml 38 45 <span type="species:ncbi:9606">patient</span>
Atypical teratoid/rhabdoid tumor in a patient with Beckwith-Wiedemann syndrome.
###end article-title 143
###begin article-title 144
Histone-deacetylase inhibitors for the treatment of cancer.
###end article-title 144
###begin article-title 145
Malignant rhabdoid tumor. A study with two established cell lines.
###end article-title 145
###begin article-title 146
Narrowing the critical region for a rhabdoid tumor locus in 22q11.
###end article-title 146
###begin article-title 147
###xml 83 88 <span type="species:ncbi:9606">human</span>
High-resolution cell cycle analysis of defined phenotypic subsets within primitive human hematopoietic cell populations.
###end article-title 147
###begin article-title 148
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human CIA30 is involved in the early assembly of mitochondrial complex I and mutations in its gene cause disease.
###end article-title 148
###begin article-title 149
Microdeletion of LIT1 in familial Beckwith-Wiedemann syndrome.
###end article-title 149
###begin article-title 150
Histone deacetylase inhibitors have a profound antigrowth activity in endometrial cancer cells.
###end article-title 150
###begin article-title 151
Regulation of FOXO3a/beta-catenin/GSK-3beta signaling by 3,3'-diindolylmethane contributes to inhibition of cell proliferation and induction of apoptosis in prostate cancer cells.
###end article-title 151
###begin article-title 152
Immunohistochemical analysis of hSNF5/INI1 in pediatric CNS neoplasms.
###end article-title 152
###begin article-title 153
p57KIP2 immunohistochemistry in early molar pregnancies: emphasis on its complementary role in the differential diagnosis of hydropic abortuses.
###end article-title 153
###begin p 154
###xml 0 21 0 21 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Competing Interests: </bold>
Competing Interests: ELizabeth Algar and David Ashley received funding from Novartis in 2008. Ricky Johnstone has commercial grants from Novartis and Merck.
###end p 154
###begin p 155
###xml 0 9 0 9 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Funding: </bold>
###xml 78 86 <span type="species:ncbi:9606">Children</span>
Funding: This work was funded by the Cancer in Kids Auxilliary (CIKA) and the Children's Cancer Centre Foundation. The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript.
###end p 155

